Sanuo Biotech: The European Unified Patent Court rejects the company's appeal against the EP4344633 patent.

Sanuo Biology announced that the company's appeal against the temporary injunction of the European Unified Patent Court on patent EP4344633 has been rejected. The temporary injunction was targeted at the company's GlucoMen iCan CGM product, with an estimated amount involved of 200,000 to 400,000 euros. The company is actively preparing for the main lawsuit and defense work. Since the main lawsuit has not yet been heard, the final judgment outcome is uncertain, and the specific impact on the company's future profits is also uncertain.